Perflubron

Perflubron (Perfluorooctyl bromide) is a contrast medium for magnetic resonance imaging and sonography. Perflubron inhibits chemokine expression and NF-κB activation. Perflubron can be emulsified with egg phospholipids (EYP) and shows exceptionally fast excretion characteristics. Perflubron has anti-inflammatory, antiviral and cytoprotective effects[1][2][3][4][5][6][7].

Product Specifications

CAS Number

[423-55-2]

Product Name Alternative

Perfluorooctyl bromide; 1-Bromoperfluorooctane; PFOB

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

NF-κB; RSV

Type

Reference compound

Related Pathways

Anti-infection; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Infection; Inflammation/Immunology

Concentration

10mM

Purity

99.98

Solubility

DMSO : 16.67 mg/mL (ultrasonic)

Smiles

FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(Br)F

Molecular Formula

C8BrF17

Molecular Weight

498.96

Precautions

H302, H315, H319, H335

References & Citations

[1]Perflubron, From Wikipedia, the free encyclopedia|[2]Perflubron|[3]Woods CM, et al. Perflubron attenuates neutrophil adhesion to activated endothelial cells in vitro. Am J Physiol Lung Cell Mol Physiol. 2000 May;278 (5) :L1008-17.|[4]Babu PB, et al. Hyperoxia-induced changes in human airway epithelial cells: the protective effect of perflubron. Pediatr Crit Care Med. 2005 Mar;6 (2) :188-94.|[5]Kishioka C, et al. Perfluorooctyl bromide (perflubron) stimulates mucin secretion in the ferret trachea. Chest. 1999 Mar;115 (3) :823-8.|[6]Haeberle HA, et al. Perflubron reduces lung inflammation in respiratory syncytial virus infection by inhibiting chemokine expression and nuclear factor-kappa B activation. Am J Respir Crit Care Med. 2002 May 15;165 (10) :1433-8.|[7]Weiss DJ, et al. Perflubron enhances adenovirus-mediated gene expression in lungs of transgenic mice with chronic alveolar filling. Hum Gene Ther. 1999 Sep 20;10 (14) :2287-93.|[8]Weiss DJ, et al. Use of perflubron to enhance lung gene expression: safety and initial efficacy studies in non-human primates. Mol Ther. 2002 Jan;5 (1) :8-15.